Literature DB >> 29034448

Synergies From Integrating Randomized Controlled Trials and Real-World Data Analyses.

Mehdi Najafzadeh1, Joshua J Gagne1, Sebastian Schneeweiss1.   

Abstract

Analyses using administrative claims databases or national registries provide estimates of benefits and harms of medications in real-world settings for large and diverse patient populations. Whereas claims-based nonrandomized studies and randomized-controlled trials (RCTs) have distinct limitations, their strengths are complementary. Integrating RCT and claims data offers substantial synergies. We propose obtaining routinely collected longitudinal claims data from RCT participants and discuss the added value of the novel evidence that can be derived from this "information overlap."
© 2017 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Year:  2017        PMID: 29034448     DOI: 10.1002/cpt.873

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  3 in total

1.  A Proposal for Value-Based Managed Entry Agreements in an Environment of Technological Change and Economic Challenge for Publicly Funded Healthcare Systems.

Authors:  Entela Xoxi; Filippo Rumi; Panos Kanavos; Hans-Peter Dauben; Iñaki Gutierrez-Ibarluzea; Olivier Wong; Guido Rasi; Americo Cicchetti
Journal:  Front Med Technol       Date:  2022-06-16

Review 2.  A Framework for Methodological Choice and Evidence Assessment for Studies Using External Comparators from Real-World Data.

Authors:  Christen M Gray; Fiona Grimson; Deborah Layton; Stuart Pocock; Joseph Kim
Journal:  Drug Saf       Date:  2020-07       Impact factor: 5.606

Review 3.  Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough?

Authors:  Emanuel Raschi; Elisabetta Poluzzi; Gian Paolo Fadini; Giulio Marchesini; Fabrizio De Ponti
Journal:  Diabetes Obes Metab       Date:  2018-08-14       Impact factor: 6.577

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.